163 related articles for article (PubMed ID: 25023999)
21. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
22. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
23. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
[TBL] [Abstract][Full Text] [Related]
24. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
25. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
26. Positron-emission tomography and computed tomography of cystic pancreatic masses.
Tann M; Sandrasegaran K; Jennings SG; Skandarajah A; McHenry L; Schmidt CM
Clin Radiol; 2007 Aug; 62(8):745-51. PubMed ID: 17604762
[TBL] [Abstract][Full Text] [Related]
27. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas.
Hsiao YC; Wu PS; Chiu NT; Yao WJ; Lee BF; Peng SL
Clin Radiol; 2011 Dec; 66(12):1197-202. PubMed ID: 21907336
[TBL] [Abstract][Full Text] [Related]
28. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
[TBL] [Abstract][Full Text] [Related]
29. Clinical usefulness of dual-time FDG PET-CT in assessment of esophageal squamous cell carcinoma.
Shum WY; Hsieh TC; Yeh JJ; Chen JH; Su CC; Liang JA; Kao CH
Eur J Radiol; 2012 May; 81(5):1024-8. PubMed ID: 21458941
[TBL] [Abstract][Full Text] [Related]
30. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
[TBL] [Abstract][Full Text] [Related]
32. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Dual-Time-Point 18F-FDG PET for Idiopathic Pulmonary Fibrosis.
Umeda Y; Demura Y; Morikawa M; Anzai M; Kadowaki M; Ameshima S; Tsuchida T; Tsujikawa T; Kiyono Y; Okazawa H; Ishizaki T; Ishizuka T
J Nucl Med; 2015 Dec; 56(12):1869-75. PubMed ID: 26359263
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
35. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
36. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
37. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
Metser U; Miller E; Lerman H; Even-Sapir E
AJR Am J Roentgenol; 2007 Nov; 189(5):1203-10. PubMed ID: 17954662
[TBL] [Abstract][Full Text] [Related]
38. Dual-time-point (18)F-FDG-PET/CT imaging in the assessment of suspected malignancy.
Chan WL; Ramsay SC; Szeto ER; Freund J; Pohlen JM; Tarlinton LC; Young A; Hickey A; Dura R
J Med Imaging Radiat Oncol; 2011 Aug; 55(4):379-90. PubMed ID: 21843173
[TBL] [Abstract][Full Text] [Related]
39. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
[TBL] [Abstract][Full Text] [Related]
40. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
